This is the authors' abstract. We don't add key points for this paper.
Interferon-induced ubiquitin (Ub)-like modifier ISG15 functions both intracellularly and as a secreted protein with cytokine-like properties. The ISG15 pathway is implicated in various diseases, including cancer and inflammatory disorders, but understanding its precise roles has been challenging due to limited availability of tools to study ISG15 biology. Here we report the development of two novel nanobodies that target human ISG15, obtained through alpaca immunization and phage display. These nanobodies, VHH ISG15-A and VHH ISG15-B , exhibit nanomolar binding affinities and recognize distinct epitopes on ISG15's C- and N-terminal domains, respectively, as demonstrated by NMR and X-ray structural analyses. Both nanobodies enable the immunoprecipitation and proteomic identification of ISGylated substrates with minimal background contamination. VHH ISG15-A is compatible with immunoblotting, and recognizes unconjugated ISG15 under denaturing conditions. Functional assays showed that VHH ISG15-A , but not VHH ISG15-B , inhibits USP16-mediated deISGylation, likely by steric hindrance at the ISG15-binding interface. These results underscore the utility of VHH ISG15-A and VHH ISG15-B as tools to study ISG15 biology.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: